18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (8), 1519-1534
- https://doi.org/10.1007/s00262-020-02560-5
Abstract
Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are of considerable clinical interest. In this study, we characterized the relationships among tumor(18)F-fluorodeoxyglucose (FDG) retention, tumor metabolic and immune phenotypes, and survival in patients with resected non-small cell lung cancer (NSCLC). We retrospectively analyzed tumor preoperative positron emission tomography (PET)F-18-FDG uptake in 59 resected NSCLCs and investigated correlations between PET parameters (SUVMax, SUVTotal, SUVMean, TLG), tumor expression of glycolysis- and immune-related genes, and tumor-associated immune cell densities that were quantified by immunohistochemistry. Tumor glycolysis-associated immune gene signatures were analyzed for associations with survival outcomes. We found that each(18)F-FDG PET parameter was positively correlated with tumor expression of glycolysis-related genes. Elevated(18)F-FDG SUV(Max)was more discriminatory of glycolysis-associated changes in tumor immune phenotypes than other(18)F-FDG PET parameters. Increased SUV(Max)was associated with multiple immune factors characteristic of an immunosuppressive and poorly immune infiltrated tumor microenvironment, including elevated PD-L1 expression, reduced CD57(+)cell density, and increased T cell exhaustion gene signature. Elevated SUV(Max)identified immune-related transcriptomic signatures that were associated with enhanced tumor glycolytic gene expression and poor clinical outcomes. Our results suggest that(18)F-FDG SUV(Max)has potential value as a noninvasive, clinical indicator of tumor immunometabolic phenotypes in patients with resectable NSCLC and warrants investigation as a potential predictor of therapeutic response to immune-based treatment strategies.Funding Information
- Conquer Cancer Foundation (12895)
- Lung SPORE (5 P50 CA070907)
- DoD PROSPECT Grant (W81XWH-07-1-0306)
- CG Johnson Foundation Advanced Scholar Program Funds
- University of Texas MD Anderson Physician Scientist Program and Lung Cancer Moon Shots Program
- Bob Mayberry Foundation
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Scholar Award)
- MD Anderson Cancer Center Support Grant (P30CA01667)
- Bruton Endowed Chair in Tumor Biology
- National Cancer Institute (R01 CA187076, R01 CA184845)
- T.J. Martell Foundation (US) Physician Scientist Program
- Melanoma SPORE Grant (P50 CA221703)
- Cancer Prevention and Research Institute of Texa (RP170401)
This publication has 65 references indexed in Scilit:
- Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancerLung Cancer, 2013
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapyNature Medicine, 2013
- 18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant ChemoradiotherapyJournal of Nuclear Medicine, 2013
- A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 2013
- Acidity Generated by the Tumor Microenvironment Drives Local InvasionCancer Research, 2013
- Rapid Disease Progression With Delay in Treatment of Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2011
- The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humansJCI Insight, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Inhibitory effect of tumor cell–derived lactic acid on human T cellsBlood, 2007